Lejla Vajzovic, MD
Ophthalmology · Durham, NCNPI 1548434921
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $475,125 of the $681,428 with a category attached, or 69.7%. 30 manufacturers reported payments, led by Alcon at 24.1% of the total. Among ophthalmology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 522 payments — averaging $1305.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$164K
- AbbVie$112K
- Astellas Pharma US Inc$70K
- Apellis Pharmaceuticals, Inc.$58K
- Genentech USA, Inc.$56K
- Bausch & Lomb Americas Inc.$47K
- plus $174K from 24 others
Across 195 payments — averaging $35,249 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$6.1M
- Ocular Therapeutix, Inc.$323K
- Apellis Pharmaceuticals, Inc.$236K
- Janssen Research & Development, LLC$165K
- Alcon Research LLC$34K
- AbbVie$12K
- plus $10K from 1 others
What the payments were for
- Consulting fees$475,12570%
- Speaking & faculty fees$150,66522%
- Travel & lodging$36,1775%
- Food & beverage$19,4513%
- Gifts$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 125 | $164,307 |
| AbbVie(2 entities) | 99 | $112,293 |
| Astellas Pharma US Inc | 18 | $69,877 |
| Apellis Pharmaceuticals, Inc. | 51 | $58,206 |
| Genentech USA, Inc. | 32 | $55,875 |
| Bausch & Lomb Americas Inc. | 32 | $46,995 |
| Ocular Therapeutix, Inc. | 33 | $42,185 |
| Alcon Research LLC | 28 | $34,608 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 19 | $17,784 |
| Dutch Ophthalmic, USA | 7 | $16,526 |
| Beaver-visitec International, Inc. | 2 | $12,500 |
| Novartis | 6 | $9,425 |
| Regeneron Healthcare Solutions, Inc. | 6 | $6,201 |
| Aerie Pharmaceuticals, Inc. | 7 | $5,311 |
| Regeneron | 5 | $5,150 |
| Eyepoint US, Inc. | 13 | $5,132 |
| Genentech, Inc. | 5 | $3,370 |
| F. Hoffmann-la Roche AG | 2 | $3,194 |
| Alimera Sciences, Inc. | 6 | $3,124 |
| Dutch Ophthalmic Research Center (international) B.v. | 1 | $2,673 |
| Oculus Surgical Inc. | 5 | $2,264 |
| Sumitomo Pharma Co., Ltd. | 1 | $2,200 |
| Astellas Pharma Global Development | 6 | $1,232 |
| Heidelberg Engineering, Inc. | 3 | $269 |
| Carl Zeiss Meditec, Inc. | 3 | $246 |
| Coherus Oncology, Inc. | 2 | $168 |
| ANI Pharmaceuticals, Inc. | 1 | $122 |
| Topcon Healthcare, Inc. | 2 | $86 |
| Neurotech Pharmaceuticals, Inc. | 1 | $76 |
| Biocryst Pharmaceuticals, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$96,561
- Constellation$94,400
- Izervay$55,149
- NGENUITY$36,655
- Unity$33,504
- Lucentis$32,997
- VABYSMO$22,536
- Syfovre$19,328
- Luxor$17,263
- FINESSE SHARKSKIN$16,188
- STELLARIS PC$15,010
- OPHTHALMIC INSTRUMENTS$15,010
- VITESSE$15,010
- EVA, combined machine$12,326
- Alcon Greishaber Finesse$12,192
- ARGOS$11,900
- XIPERE$11,192
- TISSUEBLUE$9,926
- LIGHT PIPES$9,630
- BEOVU$9,225
How this compares
$681,428 in reported general payments places this provider in the 95th percentile of 588 ophthalmology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 107 | $5,857 |
| Bromfenac Sodium | 18 | $4,040 |
| Ketorolac Tromethamine | 82 | $2,374 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 46 | $582 |
| Brimonidine Tartrate | 21 | $321 |
| Timolol Maleate | 12 | $162 |
| Latanoprost | 20 | $139 |
| Dorzolamide Hcl | 11 | $115 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Durham
- Julie WoodwardDurham$1M
- Terry KimDurham$605K
- Leon HerndonDurham$230K
- Glenn JaffeDurham$218K
- Robin VannDurham$213K
- Anthony KuoDurham$186K
- Michael RichardDurham$113K
- Priyatham MettuDurham$111K
- Jason LissDurham$69K
- Majda HadziahmetovicDurham$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.